OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and immuno-inflammation.

OSE Immunotherapeutics has a dynamic partnership business model based on innovative products that generates non-dilutive revenues and finances R&D programs. These products have real blockbuster potential and give to OSE-Immunotherapeutics, an ability to conclude global agreements at different stages of their development with major pharmaceuticals players. OSE-Immunotherapeutics actively seeks international partners for out-Licencing of compounds at all stages of clinical development of drug products.